| ¿µ¹® | toxicity | ÇÑ±Û | µ¶¼º |
|---|---|---|---|
| ¼³¸í | »ýü¿¡ ÀÖ¾î ¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº ¾à¹° ÀÛ¿ëÀ» ¸»ÇÑ´Ù. ¾à¹°À» °ú·®À¸·Î »ç¿ëÇϸé Áßµ¶À» ÀÏÀ¸Å°¸ç, ½ÉÇÑ °æ¿ì¿¡´Â Á×À½¿¡ À̸£´Âµ¥ ÀÌ´Â ¾à¹°ÀÇ ±Þ¼º µ¶¼ºÀÌ´Ù. ¸¸¼º µ¶¼ºÀº ¼Ò·®À» Àå±â°£ ¹Ýº¹ ¼·ÃëÇÏ¿´À» ¶§ÀÇ µ¶¼ºÀÌ´Ù. °£, ÄáÆÏ µî ¿©·¯ Àå±â¿Í Á¶Á÷¿¡ ´ëÇÑ µ¶¼º ¿Ü¿¡, ±âÇüÀ¯¹ß¼º, ¹ß¾Ï¼º µîµµ ¾à¹°µ¶¼ºÀÌ´Ù. ¾à¹°µ¶¼ºÀÇ °¾àÀº ±Þ¼º µ¶¼º°Ë»ç(LD50), ¸¸¼º µ¶¼º°Ë»ç, ±âÇüÀ¯¹ß°Ë»ç, ¹ß¾Ï°Ë»ç, ¹ø½Ä°Ë»ç ±âŸ ¿©·¯ µ¿¹°°Ë»ç¿¡ ÀÇÇØ ÆÇÁ¤µÈ´Ù. |
||
| ¿µ¹® | chronic lymphocytic leukemia | ÇÑ±Û | ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´ |
|---|---|---|---|
| ¼³¸í | ¹éÇ÷º´(leukemia)¶õ ºñÁ¤»óÀûÀÎ ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀÎ »óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊÇ÷¾×¿¡ ¹ÌºÐȼ¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀÎ ÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀÎ ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ ã¾Æ¿À°Ô µÈ´Ù. µû¶ó¼ ÀûÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ¡°Ô ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇÏ´Â °ñ¼ö Á¶Á÷¿¡¼´Â ÀÌ·± ºñÁ¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù. ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´Àº ¼¾ç¿¡¼´Â ºñ±³Àû ¹éÇ÷º´ Áß¿¡¼ ÈçÇÑ ÇüÀÌÁö¸¸ µ¿¾ç±Ç¿¡¼´Â ¾ÆÁÖ µå¹® ¹éÇ÷º´ÀÇ ÇüÅÂÀÌ´Ù. ´ë°³ 60¼¼ ÀÌ»óÀÇ °í·ÉÃþ¿¡¼ ¸¹ÀÌ »ý±â°í 30¼¼ ÀÌÇÏ¿¡¼´Â °ÅÀÇ Ã£¾Æº¼ ¼ö°¡ ¾ø´Ù. Ç÷¾×°Ë»ç»ó¿¡¼ ¸²ÇÁ±¸ÀÇ ¸¹Àº Áõ°¡¸¦ º¼ ¼ö°¡ ÀÖ°í, ´ë½Å¿¡ ´Ù¸¥ Ç÷¾×¼¼Æ÷µéÀº °¨¼Ò¸¦ ³ªÅ¸³½´Ù. ¹éÇ÷º´ Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ¸ç ´ë°³ Ä¡·á´Â Ç×¾ÏÁ¦¸¦ ÀÌ¿ëÇÑ ÈÇпä¹ýÀ» ¸¹ÀÌ »ç¿ëÇϸç, Æò±Õ »ýÁ¸±â°£Àº 4~5³âÀÌ´Ù. |
||
| ¿µ¹® | chronic obstructive pulmonary disease | ÇÑ±Û | ¸¸¼ºÆó¼âÆóº´ |
|---|---|---|---|
| ¼³¸í | ¸¸¼ºÀûÀ¸·Î ±âµµÀÇ Æó¼â¸¦ °¡Á®¿À´Â º´À» À̸£´Â ¸». ´ë°³ ¸¸¼º±â°üÁö¿°, ±â°üÁö õ½Ä, Æó±âÁ¾ÀÇ 3°¡Áö º´À» ¸»ÇÑ´Ù. ¸¸¼º±â°üÁö¿°À̶õ ±â°üÁöÀÇ ¸¸¼º¿°ÁõÀ» ¸»ÇÑ´Ù. ±â°üÁöÀÇ ¿°ÁõÀ¸·Î ÀÎÇØ¼ ±â°üÁöÀÇ Á¡¸·¿¡ ºÎÁ¾ÀÌ »ý±â°í ÀÌ·Î ÀÎÇØ¼ ±â°üÁöÀÇ ³»°æÀÌ Á¼¾ÆÁ®¼ ±âµµÀÇ Æó¼â¸¦ °¡Á®¿Â´Ù. ´ë°³ Èí¿¬°ú ¹ÐÁ¢ÇÑ ¿¬°üÀ» °¡Áö¸ç, È£Èí°ï¶õ, ±âħ, ±×¸®°í °¡·¡(´ë°³ »öÀÌ Çª¸£°í Á¡µµ°¡ ³ôÀº °¡·¡)°¡ Áõ»óÀ¸·Î ³ªÅ¸³´Ù. Æó±âÁ¾Àº ±â°üÁöÀÇ º®À» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ ±â°üÁö°¡ Á¦ ¸ð¾çÀ» °®ÃßÁö ¸øÇÏ°í ¹«³ÊÁö°Ô µÇ¾î ±âµµÀÇ Æó¼â°¡ ÀϾ´Â º´ÀÌ´Ù. Áï ±â°üÁö°¡ °ü ¸ð¾çÀ¸·Î ÆØÆØÇÏ°Ô ÆìÁö´Â °ÍÀ» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ °ü¸ð¾çÀ¸·Î ÆìÁöÁö ¸øÇØ °á±¹Àº ÆóÆ÷³»¿¡ °ø±â°¡ Â÷°í ÆóÆ÷º®ÀÌ ÆÄ¿µÇ°í ±â°üÁö°¡ Á¼¾ÆÁö°Ô µÇ´Â º´À» ¸»ÇÑ´Ù. ±â°üÁöõ½ÄÀ̶õ ¿©·¯ °¡Áö Àڱؿ¡ ´ëÇØ¼ ±â°üÁö°¡ °ú¹ÎÇÑ ¹ÝÀÀÀ» º¸¿©¼ »ý±â´Â ±â°üÁöÀÇ °¡¿ªÀûÀÎ Æó¼â¸¦ ÀǹÌÇÑ´Ù. Áï Á¤»óÀο¡°Ô¼´Â ±â°üÁöÀÇ Æó¼â¸¦ º¸ÀÌÁö ¾Ê´Â Àڱؿ¡ ´ëÇØ¼ ±â°üÁöÀÇ Æó¼â°¡ »ý±â°í ±× ÀÚ±ØÀÌ ¾øÀ» °æ¿ì¿¡´Â ±â°üÁöÀÇ Æó¼â°¡ ¾ø¾îÁö´Â º´À» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | chronic active hepatitis | ÇÑ±Û | ¸¸¼ºÈ°µ¿°£¿° |
|---|---|---|---|
| ¼³¸í | BÇü °£¿°À̳ª ºñAÇü£ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Ư¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀÇ Ä§À±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ Ȳ´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈÁõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù. |
||
| ¿µ¹® | test | ÇÑ±Û | °Ë»ç |
|---|---|---|---|
| ¼³¸í | ¾î¶² ´Ù¸¥ ¹°ÁúÀ» °ËÃâ, ÃøÁ¤, »ý¼ºÇϱâ À§ÇÑ Æ¯Á¤ÇÑ ÈÇйÝÀÀÀ» ÀÏÀ¸Å°´Âµ¥ »ç¿ëµÇ´Â ¹æ¹ý. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| EUROTOX | European Committee on Chronic Toxicity Hazards |
| PAT | Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili... |
| CP | candle power; capillary pressure; cardiac pacing; cardiac performance; cardiopulmonary; caudate puta... |
| CTC | Common Toxicity Criteria |
|---|---|
| DLT | Dose limiting toxicity |
| RRT | Regimen related toxicity |
| TCLP | Toxicity Characteristic Leaching Procedure |
| TIE | Toxicity Identification Evaluation |
| chronic toxicity | <pharmacology> Illness caused by repeated or long-term exposure to low doses of a toxic substance. Compare: acute toxicity. (09 Oct 1997) |
|---|---|
| toxicity test | <investigation> Controlled laboratory test to determine the toxicity of a chemical to an organism in terms of specific chemical concentrations. An acute toxicity test establishes the concentration required to kill a predetermined proportion of test organisms within a relatively short period of time, typically 4 days or less. A chronic toxicity test reveals the effects of a sublethal concentration applied throughout all or part of the life cycle. (12 Jan 1998) |
| acute toxicity | <pharmacology> Illness resulting from a single dose or exposure to a toxic substance. Compare: chronic toxicity. (06 May 1997) |
| digitalis toxicity | A result of the over-accumulation of digitalis glycosides in the body. Kidney insufficiency can be a contributing factor. Symptoms include nausea, vomiting, visual changes, blurred vision, anorexia and palpitations. Treatment is emergent as life-threatening cardiac arrhythmias are possible with higher blood levels. (27 Sep 1997) |
| digoxin toxicity | A result of the over-accumulation of digitalis glycosides in the body. Kidney insufficiency can be a contributing factor. Symptoms include nausea, vomiting, visual changes, blurred vision, anorexia and palpitations. Treatment is emergent as life-threatening cardiac arrhythmias are possible with higher blood levels. (27 Sep 1997) |
| drug toxicity | The systemic effects of a drug that are related to the overall level of the medication in the bloodstream. Drug toxicity may occur with overdosage of a medication, accumulation of the drug in the body over time or the inability of the patients body to eliminate the drug. (27 Sep 1997) |
| oxygen toxicity | A body disturbance resulting from breathing high partial pressures of oxygen; characterised by visual and hearing abnormalities, unusual fatigue while breathing, muscular twitching, anxiety, confusion, incoordination, and convulsions; although the mechanism for development of the condition is obscure, a disruption of enzymatic activity is likely, perhaps as a result of free radical formation. Synonym: oxygen poisoning. (05 Mar 2000) |
| toxicity | The quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. (18 Nov 1997) |
| toxicity tests | Tests that determine the toxicity of a substance. These include tests of clinical drugs, foods, environmental pollutants, etc. (12 Dec 1998) |
| ep toxicity | A test defined by the federal Environmental Protection Agency to check a substance for the presence of arsenic, barium, cadmium, chromium, lead, mercury, selenium, or silver. 40 CFR 261.24 defines the concentrations constituting hazardous waste and the test procedure. (05 Dec 1998) |
| anaemia of chronic disease | <disease> A form of anaemia which develops as the result of a long-term infection or illness. Chronic diseases can interfere with red blood cell production in addition to shortening red blood cell life span in the body. Symptoms are largely due to the underlying disease. Haemoglobin and haematocrit are generally low. Iron studies may be low to normal. Red blood cell indices may usually normal. (27 Sep 1997) |
| benign familial chronic pemphigus | Recurrent eruption of vesicles and bullae that become scaling and crusted lesions with vesicular borders, predominantly of the neck, groin, and axillary regions; autosomal dominant inheritance, presenting in late adolescence or early adult life. Synonym: Hailey-Hailey disease. (05 Mar 2000) |
| candidiasis, chronic mucocutaneous | A clinical syndrome characterised by development, usually in infancy or childhood, of a chronic, often widespread candidiasis of skin, nails, and mucous membranes. It may be secondary to one of the immunodeficiency syndromes, inherited as an autosomal recessive trait, or associated with defects in cell-mediated immunity, endocrine disorders, dental stomatitis, or malignancy. (12 Dec 1998) |
| granulomatous disease, chronic | A recessive x-linked defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. (12 Dec 1998) |
| persistent chronic hepatitis | A benign chronic hepatitis that may follow acute viral hepatitis A or B, or complicate bowel diseases; after six months, liver biopsy changes are mild, unlike active chronic hepatitis; rarely, if ever, progresses to cirrhosis, portal hypertension, or liver failure. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|